Abstract 461P
Background
Lung cancer is the leading cause of cancer deaths worldwide including in India. Around 80% of these are Non Small Cell Lung Cancers (NSCLC) detected in advanced stages where surgical resection is not an option and locally advanced stage patients are treated with concurrent chemoradiotherapy.
Methods
A total of 90 patients of NSCLC Stages IIIA and IIIB participated in the study conducted over the last eighteen months. They were randomized and distributed between two arms in 1:1 ratio. Their pre-treatment Pulmonary Function Tests were recorded. Participants in Arm A underwent 30 minutes of yoga session daily besides standard fractionation radiotherapy with concurrent weekly chemotherapy. Participants in Arm B received the same schedule of concurrent chemoradiotherapy but without the daily yoga session. Their post-treatment Pulmonary Function Tests were recorded at six weeks post completion of chemoradiotherapy and compared with pre-treatment values.
Results
21 participants in Arm A recorded positive changes in their FEV1 values, compared to just 3 patients in Arm B (p=0.0002), suggesting daily yoga sessions during treatment can actually help in improvement of lung function among locally advanced NSCLC patients.
Conclusions
Further multi-institutional studies with more participants should be encouraged and yoga be more maistreamed and formally incoporated into standard therapeutic regimens for the management of locally advanced non small cell lung cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract